10x Science has secured $4.8 million in seed funding to help pharmaceutical researchers interpret the flood of AI-generated molecular candidates. The startup addresses a critical gap: AI can propose drugs faster than humans can evaluate them.
Drug discovery has entered a computational paradox. Machine learning models now generate thousands of potential drug candidates in hours—far outpacing traditional screening methods. But identifying which molecules actually warrant clinical testing remains a bottleneck.
10x Science tackles this by helping researchers understand complex molecular data. The startup's platform cuts through the noise, letting pharma teams focus resources on the most promising candidates.
The $4.8 million seed round reflects investor confidence in the problem's scale. As AI models grow more powerful, the gap between discovery speed and validation only widens. Firms that can efficiently filter AI-generated compounds gain significant competitive advantage.
The pharmaceutical industry has increasingly adopted AI for drug development, reducing timelines from years to months for initial candidate identification. But converting AI predictions into viable therapies still requires human expertise and wet-lab validation.
Livestream shopping platform Whatnot has acquired AI startup Shaped to enhance its recommendation engine. The deal strengthens Whatnot's personalization capabilities as it expands into new product categories.
Amsterdam-based Monumental secured a $32 million Series B round led by Khosla Ventures. The company develops autonomous robotics and AI software for the construction industry.
Indian AI coding startup Emergent reached a $1.5 billion valuation in its latest funding round, raising $130 million in Series C and joining the unicorn club after a five-fold valuation jump in six months.
Rime, an AI platform processing over 100 million calls monthly, secured $24 million in Series A funding to expand its customer service solutions for enterprises.